Discover 250 paid clinical trials in Spokane, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 250
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
for
Mantle Cell Lymphoma
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 60+
Code: NCT05976763
Phase 3, Recruiting
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for
Smoldering Plasma Cell Myeloma
Location: Post Falls ID, Coeur d'Alene ID, Walla Walla WA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT03937635
Phase 3, Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05642572
Phase 2, Recruiting
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
for
Breast Carcinoma, Colorectal Carcinoma,
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 18+
Code: NCT06418204
Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
for
Advanced Lung Non-Small Cell Carcinoma,
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 70+
Code: NCT06096844
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04181060
Phase 3, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
for
Lung Non-Small Cell Carcinoma
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06116682
Phase 2, Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: NRG Oncology
Sex: All
Age: 45 - 70
Code: NCT05080673
Recruiting
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
for
Malignant Female Reproductive System Neoplasm,
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06126276
Phase 2, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Location: Post Falls ID, Coeur d'Alene ID, Sandpoint ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03866382
Phase 2, Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for
Lymphoma, Large B-Cell, Diffuse
Location: Post Falls ID, Vancouver WA, Portland OR, Bozeman MT,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06890884
Phase 2, Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)